Please use this identifier to cite or link to this item:
https://scidar.kg.ac.rs/handle/123456789/9569
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.rights.license | openAccess | - |
dc.contributor.author | Jovanovic I. | - |
dc.contributor.author | Pejnović, Nada | - |
dc.contributor.author | Radosavljevic, Gordana | - |
dc.contributor.author | Arsenijevic, Nebojsa | - |
dc.contributor.author | Lukic, Miodrag | - |
dc.date.accessioned | 2020-09-19T18:36:20Z | - |
dc.date.available | 2020-09-19T18:36:20Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 2162-4011 | - |
dc.identifier.uri | https://scidar.kg.ac.rs/handle/123456789/9569 | - |
dc.description.abstract | Interleukin-33, a ligand for ST2/T1, has an important role in allergy, autoimmunity and inflammation. The role of IL-33/ST2 axis in cancer is not elucidated. Using metastatic breast cancer model we provide evidence that lack of ST2 signaling led to reduced tumor growth and metastasis and enhanced anti-tumor immunity. © 2012 Landes Bioscience. | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | OncoImmunology | - |
dc.title | IL-33/ST2 axis in innate and acquired immunity to tumors | - |
dc.type | contributionToPeriodical | - |
dc.identifier.doi | 10.4161/onci.1.2.18131 | - |
dc.identifier.scopus | 2-s2.0-84859924039 | - |
Appears in Collections: | Faculty of Medical Sciences, Kragujevac |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10.4161-onci.1.2.18131.pdf | 536.42 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License